Women’s health innovation now has commercial openings with three distinct buyer groups, and each group is under different pressure.
Among employers surveyed for Business Group on Health’s 2026 Employer Health Care Strategy Survey, 58% plan to expand preventive care for women in 2026, an increase of 22 percentage points in two years. Medicaid was the primary source of payment for 40.2% of all US births in 2024, according to the CDC’s National Center for Health Statistics. On the provider side, 331 rural hospitals stopped offering obstetric services between 2011 and 2024, roughly 27% of the nation’s rural OB units, according to the Chartis Center for Rural Health.
Each of those pressures creates a commercial opening, and each belongs to a buyer with its own definition of value. In a B2B healthcare market where deals average 22 touchpoints and can take more than a year to close, women’s health companies that choose their first buyer deliberately give themselves a clearer path from pilot to paid contract.
Three Buyers With Three Definitions of Value
Self-funded employers evaluate women’s health programs against cost trends and workforce retention. The same Business Group on Health survey found employers expect a median health care cost increase of 9% for 2026, so any new benefit has to earn its place in a tightening budget. Benefits leaders look for utilization data and a credible view of total cost of care. The fertility category shows how quickly an employer benefit can shift from differentiator to baseline expectation, a dynamic covered in Women’s Health Feature: Fertility Benefits Moved Fast. Vendor Standards Didn’t.
For health plans, value is measured in claims cost and quality performance. Plans are scored on prenatal and postpartum care through NCQA’s HEDIS measures, and with Medicaid covering four in ten births, maternal care performance matters to the Medicaid managed care organizations that serve many of those members. A vendor that can show movement on those measures, or on high-cost events like NICU admissions, is speaking the plan’s language.
Health systems think in service line economics. In rural markets, Chartis links the loss of obstetric units to hospitals cutting services to stay financially viable, a clear sign of how thin those margins can run. A women’s health company selling into a health system needs to show how its product strengthens the service line, whether through referral volume and patient retention or by extending clinical capacity without adding staff.
What This Means for Vendor Positioning
Many women’s health companies hold evidence that fits one buyer better than the other two. Menopause platforms with engagement and retention data tend to find their strongest first conversations with employers. For a remote monitoring company with outcomes tied to postpartum follow-up, health plans are the more natural fit. A single pitch deck built for all three buyers leaves each one to translate the value on its own, and across a long, multi-stakeholder buying process, that translation rarely happens without the vendor’s help.
The practical step is to lead with the buyer whose metric the current evidence already meets. That choice shapes everything downstream, from the case studies a company develops to the job titles its sales team targets.
Turning This Into a Marketing Advantage
The first buyer also becomes proof for the next. Employer data on maternity costs and utilization can open conversations with the carriers and TPAs that administer those employers’ benefits. Health system partnerships that improve postpartum visit rates give vendors a quality proof point payers already track. When buyers are sequenced this way, each contract doubles as marketing material for the next segment.
Content strategy should follow the same logic. For benefits leaders, a case study opens with retention and cost trends. Plan executives see the same results framed around quality measures and claims impact, and health system audiences see them tied to service line performance. Each version draws on the same outcomes, presented in the currency that the buyer uses to make decisions.
Where This Leaves the Market
Commercial openings for women’s health innovation now exist across employers, payers, and health systems. The companies that commercialize fastest will be the ones that pick the buyer whose definition of value their evidence already meets and use that first win to open the next door.
